semaglutide biomarkers alzheimer GLP-1RA Alzheimer's hopes dashed after Novo Nordisk's miss Semaglutide ameliorates Alzheimer's disease and

[DOI] [PubMed] [Google Scholar] Berkovic SF, Bladin PF, Jones DB, Smallwood RA, Vajda FJ

Ramanau A, Kluge H, Spilke J, Eder K

Discover Our Peptide Portfolio In 2023, the FDA reviewed several peptides nominated for compounding and placed many on the 503A Category 2 list.[3] Then in 2024, the agency cited limited clinical safety data, along with concerns about immunogenicity (how the immune system might respond) and dosing variability.[4] It was a precautionary decision, and precaution is an important part of regulatory oversight

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM et al

Drug prices can vary based on the competition for treatments and insurance coverage

Brand-name medications are not foregrounded, and no guarantees are made about which options may be available